Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1815 of 2186 results for guidelines

  1. Impedance-controlled endometrial ablation for menorrhagia (IPG104)

    Summary --> This guidance has been updated and replaced by NICE guideline CG44.

  2. Cystic fibrosis: long-term azithromycin (ESUOM37)

    This evidence summary has been updated and replaced by NICE guideline NG78.

  3. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

    This evidence summary has been updated and replaced by NICE guideline NG97.

  4. Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

    This evidence summary has been updated and replaced by NICE guideline NG117.

  5. Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

    This evidence summary has been updated and replaced by NICE guideline NG131.

  6. Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

    This evidence summary has been updated and replaced by NICE guideline NG87.

  7. Type 2 diabetes: alogliptin (ESNM20)

    This evidence summary has been updated and replaced by NICE guideline NG28.

  8. Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)

    This evidence summary has been updated and replaced by NICE guideline 115.

  9. Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

    This evidence summary has been updated and replaced by NICE guideline NG80.

  10. Type 2 diabetes: lixisenatide (ESNM26)

    This evidence summary has been updated and replaced by NICE guideline NG28.

  11. Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)

    This evidence summary has been updated and replaced by NICE guideline NG80.

  12. Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

    This evidence summary has been updated and replaced by NICE guideline 115.

  13. Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

    This evidence summary has been updated and replaced by NICE guideline NG80.